Tempus AI to acquire Ambry Genetics from Konica Minolta for $600m.

Tempus AI, an American health technology company, agreed to acquire Ambry Genetics, a provider of hereditary cancer screening, from Konica Minolta, a Japanese multinational technology company, for $600m. The acquisition will provide Tempus with expanded testing capabilities for inherited cancer risk. These services are becoming more and more important for healthcare professionals navigating critical medical decisions with cancer patients and their relatives.